24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
GEFLIEVA 250MG is an Tablet medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | GEFLIEVA 250MG |
|---|---|
| Composition | Gefitinib Tablets IP 250mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Tablet |
| Packaging | Strip (3 x 10) |
| Country of Origin | India |
GEFLIEVA 250MG (Gefitinib Tablets IP 250mg) is a widely used Tablet medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
GEFLIEVA 250 MG (Gefitinib Tablets IP 250 mg) is a prescription targeted anticancer medicine containing Gefitinib 250 mg, which is primarily used for the treatment of Epidermal Growth Factor Receptor (EGFR) mutation-positive Non-Small Cell Lung Cancer (NSCLC). Gefitinib belongs to a class of medications known as Tyrosine Kinase Inhibitors (TKIs) that work by blocking specific proteins responsible for the growth and spread of cancer cells.
Non-Small Cell Lung Cancer is the most common type of lung cancer, accounting for the majority of lung cancer cases worldwide. Certain patients with NSCLC have specific EGFR gene mutations that cause uncontrolled cancer cell growth. GEFLIEVA 250 MG is specifically designed to target these mutations and inhibit the signaling pathways that promote tumor development and progression.
Unlike conventional chemotherapy, which affects both healthy and cancerous cells, Gefitinib provides a more precise and targeted approach to cancer treatment. By directly targeting EGFR-positive cancer cells, it helps slow tumor growth while minimizing damage to normal tissues.
GEFLIEVA 250 MG is commonly prescribed for:
Before starting treatment, healthcare professionals typically perform molecular testing to confirm the presence of EGFR mutations. This helps identify patients who are most likely to benefit from Gefitinib therapy.
Gefitinib has become an important part of modern precision oncology because it specifically targets cancer-driving genetic abnormalities. It is often prescribed as a first-line treatment for eligible patients and may also be used in certain advanced-stage cancer treatment plans.
Manufactured under stringent pharmaceutical quality standards, GEFLIEVA 250 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Gefitinib therapy usually require routine monitoring, including clinical assessments, liver function tests, blood investigations, and regular follow-up appointments to evaluate treatment response and manage potential side effects.
Due to its targeted mechanism and proven clinical benefits, GEFLIEVA 250 MG remains an important treatment option for patients with EGFR-positive lung cancer worldwide.
GEFLIEVA 250 MG (Gefitinib Tablets IP 250 mg) is primarily used for the treatment and management of EGFR mutation-positive lung cancer.
The medicine is widely prescribed for patients diagnosed with EGFR-positive NSCLC.
Gefitinib helps manage advanced-stage lung cancer that cannot be effectively treated with surgery alone.
The medicine may be used when cancer has spread beyond the lungs to other parts of the body.
Doctors may prescribe Gefitinib for patients with locally advanced disease.
The medicine may help manage lung cancer that returns after previous treatment.
Gefitinib is commonly used as an initial treatment option in eligible patients with EGFR mutations.
The medicine supports personalized cancer treatment based on genetic testing results.
Gefitinib helps maintain disease control and delay cancer progression.
Gefitinib belongs to a class of medicines known as Tyrosine Kinase Inhibitors (TKIs).
GEFLIEVA works by:
This targeted mechanism helps control cancer growth while preserving healthy tissues.
Like all medicines, GEFLIEVA 250 MG may cause side effects in some patients. The occurrence and severity of side effects vary among individuals.
Acne-like skin eruptions are among the most common side effects.
Patients may experience mild to moderate diarrhea during treatment.
Skin dryness and irritation may occur.
Some individuals may experience nausea.
Occasional vomiting may occur during therapy.
Reduced appetite may affect nutritional intake.
Weakness and tiredness are commonly reported.
Inflammation or sores inside the mouth may develop.
Changes in nail appearance or nail discomfort may occur.
Seek immediate medical attention if you experience:
Patients should immediately contact their healthcare provider if serious symptoms occur.
The dosage of GEFLIEVA 250 MG (Gefitinib Tablets IP 250 mg) should always be determined by a qualified oncologist.
Treatment recommendations depend on the diagnosis and genetic mutation profile.
Doctors may adjust therapy according to effectiveness and tolerability.
Liver and kidney function may influence treatment decisions.
Dosage modifications may be required if significant adverse effects develop.
Patient-specific medical factors influence treatment planning.
Before starting treatment, inform your doctor if you have:
Patients should also disclose all prescription medicines, over-the-counter drugs, supplements, and herbal products they are currently taking to avoid potential drug interactions.
Pregnant or breastfeeding women should only use this medicine if specifically recommended by a healthcare professional.
It is primarily used for the treatment of EGFR mutation-positive Non-Small Cell Lung Cancer (NSCLC).
Gefitinib is a targeted anticancer medicine that blocks EGFR signaling pathways involved in cancer cell growth.
No. It is a targeted therapy that works differently from traditional chemotherapy medicines.
Genetic testing helps determine whether the cancer contains EGFR mutations that are likely to respond to Gefitinib therapy.
Yes. Skin rash, dry skin, and nail changes are among the commonly reported side effects.
Yes. Diarrhea is one of the most common side effects and should be managed under medical supervision.
Yes. Routine blood tests, liver assessments, and clinical evaluations are important throughout treatment.
Yes. This medicine should only be used under the supervision of qualified healthcare professionals experienced in oncology and targeted cancer treatment.